01343nas a2200385   4500000000100000000000100001000000100002008004100003653001100044653002100055653006800076653007100144653004200215653002600257653001600283653004800299653003400347653003200381653004000413653004000453653004300493653002700536653002000563100001400583700001400597700001700611700001400628700001300642700001300655245024100668250001500909300001200924490000700936020001400943       2023                            d10aHumans10aCholesterol, LDL10a*Hydroxymethylglutaryl-CoA Reductase Inhibitors/therapeutic use10a*Diabetes Mellitus, Type 2/complications/drug therapy/epidemiology10a*Cardiovascular Diseases/drug therapy10aRetrospective Studies10aCholesterol10a*Atherosclerosis/complications/epidemiology10a*Stroke/epidemiology/etiology10aUnited Kingdom/epidemiology10aLow-density lipoprotein cholesterol10aMajor adverse cardiovascular events10aatherosclerotic cardiovascular disease10alipid-lowering therapy10aType 2 diabetes1 aC. Morgan1 aA. Durand1 aT. McCormack1 aE. Hughes1 aT. Berni1 aR. Lahoz00aRisk of major adverse cardiovascular events associated with elevated low-density lipoprotein cholesterol in a population with atherosclerotic cardiovascular disease with and without type 2 diabetes: a UK database analysis using the CPRD  a2023/11/30  ae0645410 v13  a2044-6055